Lixisenatide: difference between revisions
Diff·revision 9 → 10·16:27, 3 Mar 2025
Difference between revision 9 and revision 10 of Lixisenatide. 2 lines changed; the page grew by 180 bytes.
| Revision 9 — 21:52, 10 Feb 2025 CuriousCallum (talk) state the substitution in one-letter code as well, per PP:MOS 3,035 bytes +99 | Revision 10 — 16:27, 3 Mar 2025 RetatrutideRuben (talk) convert a hard-coded date to the house format 3,215 bytes +180 | ||
|---|---|---|---|
| 26 | Set beside [[LEADER trial|LEADER]] and [[SELECT trial|SELECT]], which were positive, and the exenatide outcome trial, which was neutral, the pattern within the class is mixed. Whether the differences reflect molecule, exposure profile, population or trial size is unresolved.{{r|drucker2018}} | 26 | Set beside [[LEADER trial|LEADER]] and [[SELECT trial|SELECT]], which were positive, and the exenatide outcome trial, which was neutral, the pattern within the class is mixed. Whether the differences reflect molecule, exposure profile, population or trial size is unresolved.{{r|drucker2018}} |
| 27 | 27 | ||
| + | 28 | The practical discipline this supports is to attribute outcome findings to the trial that produced them rather than to the class. See [[GLP-1 receptor agonist]].{{r|pfeffer2015}} | |
| + | 29 | ||
| 28 | == References == | 30 | == References == |
| 29 | {{reflist}} | 31 | {{reflist}} |